R Leistner1, S Gürntke, C Sakellariou, L A Denkel, A Bloch, P Gastmeier, F Schwab. 1. Institute of Hygiene and Environmental Medicine, National Reference Center for the Surveillance of Nosocomial Infections, Charité Universitätsmedizin Berlin, Hindenburgdamm 27, 12203, Berlin, Germany, rasmus.leistner@charite.de.
Abstract
PURPOSE: The burden of extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae (ESBL-E) is growing worldwide. We aimed to determine the financial disease burden attributable to ESBL-positive species in cases of bloodstream infection (BSI) due to K. pneumoniae and E. coli. METHODS: We conducted a cohort study on patients with BSI due to K. pneumoniae or E. coli between 2008 and 2011 in our institution. Data were collected on true hospital costs, length of stay (LOS), basic demographic parameters, underlying diseases as Charlson comorbidity index (CCI) and ESBL positivity of the pathogens. Multivariable regression analysis on hospital costs and length of stay was performed. RESULTS: Overall we found 1,851 consecutive cases of ESBL-E BSI, 352 (19.0%) cases of K. pneumoniae BSI and 1,499 (81.0%) cases of E. coli BSI. Sixty-six of E. coli BSI (18.8%) and 178 of K. pneumoniae BSI (11.9%) cases were due to ESBL-positive isolates, respectively (p = 0.001). 830 (44.8%) cases were hospital-onset, 215 (61.1%) of the K. pneumoniae and 615 (41.0%) of the E. coli cases (p < 0.001). In-hospital mortality was overall 19.8, 25.0% in K. pneumoniae cases and 18.5% in E. coli cases (p = 0.006). Increased hospital costs and length of stay were significantly associated to BSI with ESBL-positive K. pneumoniae. CONCLUSION: In contrast to BSI due to ESBL-positive E. coli, cases of ESBL-positive K. pneumoniae BSI were associated with significantly increased costs and length of stay. Infection prevention measures should differentiate between both pathogens.
PURPOSE: The burden of extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae (ESBL-E) is growing worldwide. We aimed to determine the financial disease burden attributable to ESBL-positive species in cases of bloodstream infection (BSI) due to K. pneumoniae and E. coli. METHODS: We conducted a cohort study on patients with BSI due to K. pneumoniae or E. coli between 2008 and 2011 in our institution. Data were collected on true hospital costs, length of stay (LOS), basic demographic parameters, underlying diseases as Charlson comorbidity index (CCI) and ESBL positivity of the pathogens. Multivariable regression analysis on hospital costs and length of stay was performed. RESULTS: Overall we found 1,851 consecutive cases of ESBL-E BSI, 352 (19.0%) cases of K. pneumoniae BSI and 1,499 (81.0%) cases of E. coli BSI. Sixty-six of E. coli BSI (18.8%) and 178 of K. pneumoniae BSI (11.9%) cases were due to ESBL-positive isolates, respectively (p = 0.001). 830 (44.8%) cases were hospital-onset, 215 (61.1%) of the K. pneumoniae and 615 (41.0%) of the E. coli cases (p < 0.001). In-hospital mortality was overall 19.8, 25.0% in K. pneumoniae cases and 18.5% in E. coli cases (p = 0.006). Increased hospital costs and length of stay were significantly associated to BSI with ESBL-positive K. pneumoniae. CONCLUSION: In contrast to BSI due to ESBL-positive E. coli, cases of ESBL-positive K. pneumoniae BSI were associated with significantly increased costs and length of stay. Infection prevention measures should differentiate between both pathogens.
Authors: Lena M Biehl; Martin Schmidt-Hieber; Blasius Liss; Oliver A Cornely; Maria J G T Vehreschild Journal: Crit Rev Microbiol Date: 2014-02-04 Impact factor: 7.624
Authors: M E A de Kraker; M Wolkewitz; P G Davey; W Koller; J Berger; J Nagler; C Icket; S Kalenic; J Horvatic; H Seifert; A Kaasch; O Paniara; A Argyropoulou; M Bompola; E Smyth; M Skally; A Raglio; U Dumpis; A Melbarde Kelmere; M Borg; D Xuereb; M C Ghita; M Noble; J Kolman; S Grabljevec; D Turner; L Lansbury; H Grundmann Journal: J Antimicrob Chemother Date: 2010-11-23 Impact factor: 5.790
Authors: E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson Journal: Clin Microbiol Infect Date: 2014-01 Impact factor: 8.067
Authors: Sandra K Thygesen; Christian F Christiansen; Steffen Christensen; Timothy L Lash; Henrik T Sørensen Journal: BMC Med Res Methodol Date: 2011-05-28 Impact factor: 4.615
Authors: Matthias I Gröschel; Till F Omansen; Wiel de Lange; Tjip S van der Werf; Mariëtte Lokate; Erik Bathoorn; Onno W Akkerman; Ymkje Stienstra Journal: Am J Trop Med Hyg Date: 2016-01-11 Impact factor: 2.345
Authors: Joshua T Thaden; Yanhong Li; Felicia Ruffin; Stacey A Maskarinec; Jonathan M Hill-Rorie; Lisa C Wanda; Shelby D Reed; Vance G Fowler Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: Sin Young Ham; Hyungul Jung; Kyoung-Ho Song; Hyeonju Jeong; Jongtak Jung; Song Mi Moon; Jeong Su Park; Nak-Hyun Kim; Eun Sun Jang; Jin-Wook Kim; Sook-Hyang Jeong; Eu Suk Kim; Hong Bin Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2022-10-13 Impact factor: 5.103
Authors: Kathryn L McDonald; Sarah Garland; Carolee A Carson; Kimberly Gibbens; E Jane Parmley; Rita Finley; Melissa C MacKinnon Journal: JAC Antimicrob Resist Date: 2021-02-14
Authors: Christian Sakellariou; Stephan Gürntke; Ivo Steinmetz; Christian Kohler; Yvonne Pfeifer; Petra Gastmeier; Frank Schwab; Axel Kola; Maria Deja; Rasmus Leistner Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240